Should patient groups accept money from drug companies? Yes

BMJ

Volumn 334, Issue 7600, 2007, Pages 934-

  Kent, Alastair ^a  

^a Genetic Interest Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CELECOXIB; ROFECOXIB; TRASTUZUMAB;

CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG SAFETY; FINANCIAL MANAGEMENT; FUNDING; HEALTH SERVICE; HUMAN; IDEOLOGY; MEDICAL RESEARCH; MEDICAL SOCIETY; MENTAL HEALTH; MONEY; NOTE; ORGANIZATION AND MANAGEMENT; PATIENT ATTITUDE; PATIENT PARTICIPATION; PRIORITY JOURNAL; REIMBURSEMENT; WORLD HEALTH ORGANIZATION;

DRUG INDUSTRY; GIFT GIVING; INTERPROFESSIONAL RELATIONS; SELF-HELP GROUPS;

EID: 34249305544     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.39185.461968.AD     Document Type: Article

References (4)

1. Charity Commission. Stand and deliver. Liverpool: Charity Commission, 2007. www.charity-commission.gov.uk/Library/publications/pdfs/RS15text.pdf
2. Day M. Who's funding WHO? BMJ 2007; 334: 338–340.
3. Association of British Pharmaceutical Industry. The pharmaceutical industry and patient groups. www.abpi.org.uk/press/media_briefings_06_ntfrs_0c5204e4/patient_groups06.pdf
4. Association of British Pharmaceutical Industry. Patient groups, industry support and medicines. www.abpi.org.uk/publications/briefings/patientgroups_medicines.pdf